Christopher Murray Net Worth & Insider Trades
Christopher Murray - CHIEF TECHNICAL OPERATIONS, Blueprint Medicines Corp
What is Christopher Murray's Net Worth?
The current estimated net worth of Blueprint Medicines Corp's CHIEF TECHNICAL OPERATIONS, Christopher Murray, is estimated to be about $1.51M . Christopher Murray owns about 25,695 units of Blueprint Medicines Corp common stock. In the last 6 years at Blueprint Medicines Corp, Christopher Murray has sold an estimated value of $617.56K worth.
What is Christopher Murray's Past Insider Trading?
Christopher Murray's largest sale order was 5,000 units , worth over $313.6K on August 8, 2022. In total, Christopher Murray has made about 11 transactions over 6 years of their time at Blueprint Medicines Corp. Christopher Murray usually trades in March, with the busiest year in 2022. The most recent transaction was a sale order of 1,875 units , worth over $85.64K on March 8, 2023.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Christopher Murray
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
InsideArbitrage
What is Christopher Murray's' Mailing Address?
- Mailing address is C/o Blueprint Medicines Corporation 38 Sidney Street, Suite 200 Cambridge MA 02139 MA
Blueprint Medicines Corp Executive Compensation
Name |
Year
|
Salary
|
Total
|
|---|---|---|---|
| Jeffrey W. Albers | 2020 | $645,000 | $6,344,667 |
| Jeffrey W. Albers | 2019 | $590,000 | $9,362,371 |
| Jeffrey W. Albers | 2018 | $541,144 | $9,740,799 |
| Michael Landsittel | 2020 | $379,575 | $2,014,974 |
| Michael Landsittel | 2019 | $345,000 | $1,958,720 |
| Michael Landsittel | 2018 | $281,678 | $1,740,610 |
| Fouad Namouni, M.D. | 2020 | $186,154 | $6,668,732 |
| Fouad Namouni, M.D. | 2019 | - | - |
| Fouad Namouni, M.D. | 2018 | - | - |
| Kathryn Haviland | 2020 | $460,944 | $2,363,556 |
| Kathryn Haviland | 2019 | $431,830 | $3,090,423 |
| Kathryn Haviland | 2018 | $392,589 | $2,601,762 |
| Tracey L. McCain, Esq. | 2020 | $453,301 | $2,346,428 |
| Tracey L. McCain, Esq. | 2019 | $437,972 | $2,900,568 |
| Tracey L. McCain, Esq. | 2018 | $425,216 | $2,647,962 |
| No matching records found | |||
Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837021004557/tmb-20210602xdef14a.htm
What are Blueprint Medicines Corp's Past Insider Trades?
Blueprint Medicines Corp's most recent insider trade came on August 28, 2023 by Jeffrey Albers who sold 25,000 units worth $1.25M . In the last 8 years, insiders at Blueprint Medicines Corp have sold an estimated value of $176.92M and bought an estimated value of $17.68M worth of shares. Insider trading is most common in March, with the busiest year in 2020. The most active traders at the company are Jeffrey Albers, Kate Haviland, CHIEF EXECUTIVE OFFICER, and Ariel Hurley, PRINCIPAL ACCOUNTING OFFICER .
Blueprint Medicines Corp Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||